Synaptosomal-associated protein 29 is required for the autophagic degradation of hepatitis B virus.


Journal

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484

Informations de publication

Date de publication:
05 2019
Historique:
pubmed: 12 2 2019
medline: 2 6 2020
entrez: 12 2 2019
Statut: ppublish

Résumé

Hepatitis B virus (HBV) replication and envelopment is dependent on cellular autophagy. Previously, we have provided evidence for the extensive lysosomal degradation of HBV virions and the hepatitis B surface antigen (HBsAg), which is likely controlled by autophagosome-lysosome fusion. Synaptosomal-associated protein 29 (SNAP29) has been identified as a protein specifically mediating autophagosome-lysosome fusion. Thus, in the present study, we addressed the hypothesis that SNAP29 is required for the autophagic degradation of HBV virions and HBsAg. We found that silencing SNAP29 significantly increased the number of autophagosomes and concomitantly promoted HBV replication and HBsAg production. Conversely, SNAP29 overexpression decreased HBV production. Consistent with this, SNAP29 modulated HBV production by interacting with vesicle-associated membrane protein 8 (VAMP8) and synergistically regulated HBV replication with Rab7 complexes. Moreover, the production and release of the small HBsAg is strongly regulated by SNAP29 expression, suggesting that its export occurs partly through the autophagic pathway. Our findings provide new evidence, strongly suggesting that autophagic degradation critically determines the production of HBV virions and HBsAg and that this is controlled by the SNAP29-VAMP8 interaction.-Lin, Y., Wu, C., Wang, X., Liu, S., Kemper, T., Li, F., Squire, A., Zhu, Y., Zhang, J., Chen, X., Lu, M. Synaptosomal-associated protein 29 is required for the autophagic degradation of hepatitis B virus.

Identifiants

pubmed: 30742775
doi: 10.1096/fj.201801995RR
doi:

Substances chimiques

Hepatitis B Surface Antigens 0
Qb-SNARE Proteins 0
Qc-SNARE Proteins 0
R-SNARE Proteins 0
RNA, Small Interfering 0
SNAP29 protein, human 0
VAMP8 protein, human 0
Serum Albumin, Bovine 27432CM55Q

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6023-6034

Auteurs

Yong Lin (Y)

Institute of Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Chunchen Wu (C)

State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.

Xueyu Wang (X)

Institute of Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Shi Liu (S)

Institute of Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, China.

Thekla Kemper (T)

Institute of Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Fahong Li (F)

Institute of Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.

Anthony Squire (A)

Institute for Experimental Immunology and Imaging, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Ying Zhu (Y)

State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, China.

Jiming Zhang (J)

Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.

Xinwen Chen (X)

State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.

Mengji Lu (M)

Institute of Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH